National Coverage Analysis (NCA) View Public Comments

Percutaneous Transluminal Angioplasty (PTA) and Stenting of the Renal Arteries

Public Comments

Commenter Comment Information
Sugarman, Mitchell Title: Sr. Director - Health Economics, Policy & Payment
Organization: Medtronic CardioVascular
Date: 12/20/2007
Comment:

Dear Dr. Phurrough,

Medtronic, the world’s leading medical technology company specializing in implantable and interventional therapies that alleviate pain, restore health and extend life, supports CMS’s proposed decision to make no change in the current coverage policy addressing PTA of the renal arteries (Pub. 100-3, 20.7, B1).

CMS’s proposed decision provides Medicare beneficiaries equal access to therapy options that are available to the general community of “patients in whom there

More

Zwolak, Robert Organization: Society for Vascular Surgery
Date: 12/20/2007
Comment:

December 20, 2007

Lawrence Schott, MD, MS
Coverage and Analysis Group
Centers for Medicare and Medicaid Services
Department of Health and Human Services
7500 Security Blvd.
Baltimore, MD 21244

RE: Proposed Decision Memo for Percutaneous Transluminal Angioplasty (PTA) and Stenting of Renal Arteries (CAG-00085R4)

Dear Dr. Schott:

On behalf of the 2,300 members of the Society for Vascular Surgery (SVS), we offer the following comments on the Centers for Medicare &

More

Cooper, Liesl Date: 12/20/2007
Comment:

Steve Phurrough, MD, MPA,
Director Coverage and Analysis Group,
Centers for Medicare and Medicaid Services,
7500 Security Boulevard,
Baltimore, MD, 21244

Title of NCA: Percutaneous Transluminal Angioplasty (PTA) and Stenting of the Renal Arteries (CAG-00085R4)

Dear Dr. Phurrough:

Cordis welcomes the opportunity to comment on this important subject.

Cordis strongly supports the draft recommendation to retain existing coverage for this important

More

Patel, Parashar Title: Vice President, Health Economics & Reimbursement
Organization: Boston Scientific Corporation
Date: 12/20/2007
Comment:

December 20, 2007

Steve Phurrough, MD, MPA
Director, Coverage and Analysis Group
Centers for Medicare and Medicaid Services
Department of Health and Human Services
7500 Security Boulevard, Mail Stop C1-09-06
Baltimore, MD 21244

Re: Proposed Decision Memo for Percutaneous Transluminal Angioplasty (PTA) and Stenting of the Renal Arteries (CAG-00085R4)

Dear Dr. Phurrough:

Boston Scientific Corporation’s Peripheral Interventions

More

Weiner, MD, FSCAI, Bonnie Title: President
Organization: Society for Cardiovascular Angiography and Interventions
Date: 12/20/2007
Comment:

December 20, 2007

Steve Phurrough, MD, MPA
Director, Coverage and Analysis Group

RE: Comment on Proposed Decision Memo for Percutaneous Transluminal Angioplasty (PTA) and Stenting of the Renal Arteries (CAG-00085R4)

On behalf of the Society for Cardiovascular Angiography and Intervention, we would like to congratulate the Centers for Medicare and Medicaid Services on their insightful proposed decision on coverage for percutaneous transluminal angioplasty and

More

Collins, Allan Title: President
Organization: National Kidney Foundation
Date: 12/18/2007
Comment:

The National Kidney Foundation (NKF) appreciates the opportunity to submit comments on the proposed National Coverage Decision (NCD) memo for Percutaneous Transluminal Angioplasty (PTA) and Stenting of the Renal Arteries (CAG-00085R4).

We recognize that there are no published randomized controlled clinical trials comparing angioplasty with stent placement to aggressive medical therapy. The latter usually includes some combination of anti-hypertensive drugs, a statin, and

More

Hopkins, Dawn Title: Director of Reimbursement & Health Policy
Organization: Society of Interventional Radiology
Date: 12/18/2007
Comment:

December 18, 2007

Steve Phurrough, MD, MPA
Director, Coverage and Analysis Group
Centers for Medicare & Medicaid Services
Room C1-13-18
Mail Stop C1-09-06
7500 Security Boulevard
Baltimore MD 21244-1850

***Comments submitted electronically via CMS Web site, http://www.cms.hhs.gov/mcd/viewdraftdecisionmemo.asp?id=202 and Email, Steve.Phurrough@cms.hhs.gov respectively***

RE: NCA for Percutaneous Transluminal Angioplasty (PTA) and Stenting of

More

chatham, jean Date: 12/11/2007
Comment:

I read with interest the position that CMS is taking on RAS. I am a simple interventional cardiologist blessed with access to world class facilites in rural Arizona. Though our hosptial is not engaged in leading edge research, it takes care of people. I would agree that treatement of hypertension is rather complex. However, in selected cases, RAS is the cause of the patient''s hypertension. As a clincian it is very difficult to tell a patient who is having side effects from three to six BP

More

Motew, Stephen Date: 12/10/2007
Comment:

I am a vascular surgeon practicing both open surgical and percutaneous endovascular treatment of renal artery stenosis. I feel coverage should be limited to outcomes-based indications. Unfortunately there are few randomized trials however general consensus suggests: Patients presumed to have renovascular hypertension should fit into high risk groups for this disease, and have documented failure of medical therapy(>3 drugs) or the presence of significant end-organ manifestations despite

More